Dr. Reddy’s Revolutionizes Gastrointestinal Health with the Launch of Colozo® for Chronic Constipation

A New Era in Pharmaceutical Innovations for Digestive Wellness

Dr. Reddy’s Laboratories, a global pharmaceutical leader, has announced a significant advancement in the treatment of gastrointestinal disorders. The company has launched Colozo®, a first-in-class medication for adults suffering from Chronic Idiopathic Constipation (CIC). This launch marks a pivotal moment for healthcare in India, offering new hope to millions affected by this condition.

Understanding the Burden of Chronic Constipation

More Than Just a Minor Inconvenience

Chronic constipation is a prevalent and often debilitating condition that significantly impacts a person’s quality of life. Unlike occasional constipation, CIC is a long-term disorder characterized by persistent difficulty in passing stools, infrequent bowel movements, and a sensation of incomplete evacuation. The discomfort and distress caused by this condition can interfere with daily activities and overall well-being.

Introducing Colozo®: A Breakthrough in Treatment

Harnessing the Power of a Novel Mechanism

Colozo®, with its active ingredient Linaclotide, represents a new frontier in the management of CIC. It is a guanylate cyclase-C (GC-C) agonist, a class of drugs that works by increasing fluid secretion in the intestines and accelerating intestinal transit. This innovative mechanism of action provides a targeted approach to relieving the symptoms of chronic constipation.

Key Highlights of Colozo®:

• First-in-Class: The first GC-C agonist to be approved and launched in India for the treatment of CIC.
• Clinically Proven: Backed by robust clinical evidence and approved by the U.S. Food and Drug Administration (USFDA) for both CIC and Irritable Bowel Syndrome with Constipation (IBS-C).
• Differentiated Solution: Offers a novel therapeutic option for patients who have not found relief with existing treatments.

Dosage and Availability

Colozo® will be available in two strengths to cater to the diverse needs of patients.

Dr. Reddy’s Commitment to Patient-Centric Innovation

A Vision for a Healthier Future

The launch of Colozo® is a testament to Dr. Reddy’s unwavering commitment to its “Good Health Can’t Wait” philosophy. By bringing innovative and effective treatments to the Indian market, the company is not only expanding its portfolio of novel drugs but also addressing the unmet needs of patients. This initiative is a significant step towards Dr. Reddy’s goal of serving over 1.5 billion patients by 2030.

Read the Official Press Release Of Dr. Reddy’s launches Linaclotide (Colozo®
) a novel drug

M.V. Ramana, Chief Executive Officer of Branded Markets (India and Emerging Markets) at Dr. Reddy’s, expressed his enthusiasm for the launch, stating, “Colozo® represents a breakthrough in addressing the unmet needs of patients and enhancing their quality of life. We are dedicated to providing differentiated, USFDA-approved solutions that are backed by robust clinical evidence.”